History

Founded in 1997 based on research at the Norwegian Cancer Hospital. Transforming from a technology platform based company to a specialty pharma – The Bladder Cancer Company.

Photocure was founded by the Norwegian Radium Hospital to develop and commercialize a promising photodynamic non-melanoma skin cancer product with a vision to become a global leader in photodynamic technology.

Today Photocure is focusing on bladder cancer with the aim to deliver transformative solutions to improve the lives of bladder cancer patients. We operate in the Nordic and the US with 60 highly skilled employees and through partners in other territories.

 

2018

  • FDA Approval of New Indications for Blue Light Cystoscopy with Cysview®

2017

  • Photocure files supplemental New Drug Application with FDA for Blue Light. Cystoscopy (BLC™) with Cysview®.
  • Allumera® divested to Bellus.

2016

  • Blue light cystoscopy with Hexvix®/Cysview® recommended in the new AUA/SUO guidelines.
  • Hexvix® marketing authorization approval in Australia.
  • Hexvix® granted EU approval for prefilled syringe product packaging.

2015

  • Hexvix® licensed by Juno Pharmaceuticals in Australia and New Zealand.
  • Cysview® licensed by BioSyent Pharma in Canada.
  • Hexvix® recommended in NICE Guidelines, UK.
  • Agreement with US FDA for Cevira® Phase III registration program.

2014

  • Cevira® clinical program phase III ready.
  • Licensing agreement with Salix terminated.

2013

  • Positive results of phase 2b Cevira® study.
  • Visonac® is Phase III ready.

2012

  • Cysview® launch by Photocure in the US.
  • Exit Allumera® US business.

2011

  • Allumera® launched in the US.
  • Hexvix® licensed by Ipsen in EU.

2010

  • Photocure Inc. established in the US.
  • Lumacan® licensed to Salix.
  • Cysview® approved in the US.

2009

  • Metvix®/Aktilite® divested to Galderma S.A.
  • 2008 Metvix®/Aktilite® approved in the US.
  • PCI Biotech divested from Photocure.

2007

  • Hexvix® Phase III study completed inclusion.
  • Signed partnership agreement with Salix for Lumacan®.

2006

  • Hexvix® launched in the EU.
  • Hexvix® licensed to GE Healthcare.

2005

  • Hexvix® launched in the Nordics.
  • Hexvix® approved in the EU/EEA.

2004

  • First approval for Hexvix®.

2003

  • Galderma S.A launches Metvix®.

2002

  • Metvix® launched in the Nordics.

2001

  • Metvix® licensed to Galderma S.A.
  • First approval for Metvix®.

2000

  • Listed in the Oslo Stock Exchange (OSE).

1997

  • First full time employee.